Relationship of bariatric surgery to Müllerian-inhibiting substance levels

Fertility and Sterility

Volumn 90, Issue 1, 2008, Pages 221-224

  Merhi, Zaher O ^a   Minkoff, Howard ^a   Feldman, Joseph ^a   Macura, Jerzy ^a   Rodriguez, Carlos ^a   Seifer, David B ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

ADULT; ARTICLE; BARIATRIC SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERTILITY; HUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGE FACTORS; ANTI-MULLERIAN HORMONE; BARIATRIC SURGERY; BODY MASS INDEX; DOWN-REGULATION; FEMALE; HUMANS; MIDDLE AGED; OBESITY, MORBID; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 45849085436     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.05.073     Document Type: Article

References (24)

1. Hedley A.A., Ogden C.L., Johnson C.L., Carroll M.D., Curtin L.R., and Flegal K.M. Prevalence of overweight and obesity among U.S. children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
2. Santry H.P., Gillen D.L., and Lauderdale D.S. Trends in bariatric surgical procedures. JAMA 294 (2005) 1909-1917
3. Ficicioglu C., Kutlu T., Baglam E., and Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 85 (2006) 592-596
4. Seifer D.B., MacLaughlin D.T., Christian B.P., Feng B., and Shelden R.M. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77 (2002) 468-471
5. Seifer, DB, MacLaughlin DT. Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. In press.
6. De Vet A., Laven J.S., de Jong F.H., Themmen A.P., and Fauser B.C. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77 (2002) 357-362
7. Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., and Tapanainen J.S. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 20 (2005) 1820-1826
8. Fleming R., Harborne L., MacLaughlin D.T., Ling D., Norman J., Sattar N., et al. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 83 (2005) 130-136
9. Nakhuda G.S., Chu M.C., Wang J.G., Sauer M.V., and Lobo R.A. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 85 (2006) 1541-1543
10. Freeman E.W., Gracia C.R., Sammel M.D., Lin H., Lim L.C., and Strauss III J.F. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 87 (2007) 101-106
11. Seifer DB, Golub ET, Lambert-Messerlian G, Springer G, Holman S, Moxley M, et al. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertil Steril. Published online April 4, 2007.
12. Cook C.L., Siow Y., Taylor S., and Fallat M.E. Serum mullerian inhibiting substance levels during normal menstrual cycles. Fertil Steril 73 (2000) 859-861
13. Hehenkamp W.J., Looman C.W., Themmen A.P., de Jong F.M., Te Velde E.R., and Broekmans F.J. Anti-mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 91 (2006) 4057-4063
14. La Marca A., Stabile G., Carducci Artenisio A., and Volpe A. Serum anti-mullerian hormone throughout the human menstrual cycle. Hum Reprod 21 (2006) 3103-3107
15. Hudson P.L., Dougas I., Donahoe P.K., Cate R.L., Epstein J., Pepinsky R.B., et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 70 (1990) 16-22
16. Merhi Z.O. Weight loss by bariatric surgery and subsequent fertility. Fertil Steril 87 (2007) 430-432
17. Eid G.M., Cottam D.R., Velcu L.M., Mattar S.G., Korytkowski M.T., Gosman G., et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis 1 (2005) 77-80
18. Deitel M., Stone E., Kassam H.A., Wilk E.J., and Sutherland D.J. Gynecologic-obstetric changes after loss of massive excess weight following bariatric surgery. J Am Coll Nutr 7 (1988) 147-153
19. Bilenka B., Ben-Shlomo I., Cozacov C., Gold C.H., and Zohar S. Fertility, miscarriage and pregnancy after vertical banded gastroplasty operation for morbid obesity. Acta Obstet Gynecol Scand 74 (1995) 42-44
20. Martin L.F., Finigan K.M., and Nolan T.E. Pregnancy after adjustable gastric banding. Obstet Gynecol 95 (2000) 927-930
21. Marceau P., Kaufman D., Biron S., Hould F.S., Lebel S., Marceau S., et al. Outcome of pregnancies after biliopancreatic diversion. Obes Surg 14 (2004) 318-324
22. Sheiner E., Menes T.S., Silverberg D., Abramowicz J.S., Levy I., Katz M., et al. Pregnancy outcome of patients with gestational diabetes mellitus following bariatric surgery. Am J Obstet Gynecol 194 (2006) 431-435
23. Di Frega A.S., Dale B., Di Matteo L., and Wilding M. Secondary male factor infertility after Roux-en-Y gastric bypass for morbid obesity: case report. Hum Reprod 20 (2005) 997-998
24. La Marca A., Orvieto R., Giulini S., Jasonni V.M., Volpe A., and De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 82 (2004) 970-972